<DOC>
	<DOCNO>NCT02628860</DOCNO>
	<brief_summary>This phase II study evaluate safety efficacy Ferinject® reduce perioperative transfusion iron deficiency anemia patient anticipate pancreatoduodenectomy .</brief_summary>
	<brief_title>Efficacy Ferric Carboxymaltose ( Ferinject® ) Anemic Patients Anticipating Pancreatoduodenectomy</brief_title>
	<detailed_description>Primary objective : Perioperative transfusion rate ( include preop , intraop , postop≦7 day ) . Secondary objective : Postoperative complication , hospital stay , change hematological parameter ( Hb , ferritin , transferrin saturation ( TSAT ) change Ferinject® injection ) , adverse effect Ferinject® injection .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>≥19 year old anticipate PD preoperative Hb Female 7.011.9g/dl Male 7.012.9g/dl sign write informed consent concurrent medical condition ( ) would prevent compliance participation jeopardize health patient hypersensitivity component formulation active severe infection/inflammation history transfusion , erythropoietin , &gt; 500 mg intravenous iron administration within 4 week prior screen . history acquire iron overload . MCV &gt; 95µm3 TSAT &gt; 35 % patient preoperative Hb &lt; 7 g/dl pregnancy lactation decrease renal function ( defined creatinine clearance &lt; 50 L/min/1.73m2calculated eGFR ( MDRD ) ) chronic liver disease increase liver enzyme ( ALT , AST ) &gt; 5 time upper limit normal range</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ferric carboxymaltose</keyword>
	<keyword>Ferinject®</keyword>
	<keyword>pancreatoduodenectomy</keyword>
</DOC>